What changed in this filing

/stocks — the workspaceLOADING

Item 5. Market for Registrant’s Common Equity

2024-03-28 compared with 2023-03-31 · 7 added, 45 removed, 29 unchanged (64% of the section changed)

23 unchanged sentences

Plan category

of securities to

be issued upon exercise

of outstanding options,

warrants and rights

Weighted average

exercise price of

outstanding options,

warrants, and rights ($)

of securities

remaining available for

future issuance under

equity compensation

plans (excluding

securities reflected in

column a) (#)

Number of securities to be issued upon

exercise of outstanding options, warrants and rights

Weighted average exercise price of

outstanding options, warrants, and rights ($)

Number of securities remaining available

for future issuance under equity compensation plans (excluding outstanding options and warrants)

As of December 31, 2023

1 unchanged sentence

Equity compensation plans not approved by security holders

A summary of the status of our equity grants and

changes is set forth below:

(1) On November 10, 2017, the board of directors adopted the

2017 Equity Incentive Plan (the “Plan”) pursuant to which we can issue up to 1,500,000 shares of common stock pursuant to

non-qualified stock options, restricted stock grants and other equity-based incentives.

On February 19, 2021, the board of directors

amended the Plan increasing the shares we can issue under the plan to 5,000,000 shares of common stock pursuant to non-qualified stock

options, restricted stock grants and other equity-based incentives, and the amendment to the Plan became effective upon the closing of

the agreements with QFL, which was February 22, 2021.

At December 31, 2022, 1,760,000 shares are available under the plan.

In connection with the increase in the shares

of common stock issuable pursuant to the plan, the board in 2021;

● granted restricted stock grants for 100,000 shares, which

vested immediately, to each of three consultants pursuant to agreements with the consultants;

● granted restricted stock grants for a total of 690,000 shares

to our directors, Jon C.

Scahill (490,000 shares), Timothy J.

Scahill (100,000 shares) and Dr.

Carroll (100,000 shares) as

compensation for services rendered;

● granted a restricted stock grant to Ryan T.

Logue for 50,000

shares upon his acceptance of his appointment as a director;

● granted ten-year non-qualified stock options to purchase

300,000 shares to each of three consultants pursuant to agreements with the consultants, the options to vest as provided in their agreements;

● granted a ten-year non-qualified stock option to purchase

600,000 shares to Jon C.

Scahill, which vest in installments as described under Item 11.

Executive Compensation.

Recent Sales of Unregistered Securities

We did not sell any unregistered securities during

the year ended December 31, 2022 other than issuances that were reported in our SEC filings.

the year ended December 31, 2023.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 5. Market for Registrant’s Common Equity